摘要
人组织型纤溶酶原激活剂(t-PA)是一种高效特异的溶血栓药物,但天然的t-PA存在半衰期短,有潜在的引起颅内出血的危险等缺点,因而限制了它的广泛应用。世界各国的科研人员利用了分子设计和基因工程等技术,构建了一系列的t-PA突变体,旨在提高对纤维蛋白的亲和力,延长半衰期,提高纤溶效率,减少颅内出血的危险。综述了t-PA的结构和功能、对t-PA结构的改造,以及一系列t-PA突变体的研究现状及进展情况。
Human tissue-type plasminogen activator （t-PA） is a medicine used in thrombolytic treatment efficiently, hs appli-cation was limited by its defects, such as short half life and leading to blood in skull. Scientists have constructed a series of t-PA mutants which improved the appetency with fibrin, prolonged its half life, increased the efficiency of fibrinolysis and reduce the danger of blood in skull by adopting molecule design and gene engineering technology. The subject introduces the structure and function of t-PA, discusses alterations to t-PA structure and sorts of t-PA mutant.
出处
《农产品加工（下）》
2008年第7期141-143,146,共4页
Farm Products Processing
关键词
溶栓剂
基因工程
t-PA突变体
表达
thrombolytic agents
gene engineering
t-PA mutant expression
